PATRYS LIMITED - Announcements

Market Cap $18.51M Add to my watchlist

Healthcare Biotechnology

Patrys Limited is an Australia-based company, which is focused on the development of its... Patrys Limited is an Australia-based company, which is focused on the development of its deoxymab platform of cell-penetrating antibodies as therapies for a range of different cancers. The Company's deoxymab platform is based on the deoxymab 3E10 antibody that was identified as an autoantibody in a mouse model of the human disease systemic lupus erythematosus. It has developed two humanized forms of deoxymab 3E10, both of which have improved activity over the original deoxymab 3E10 antibody: PAT-DX1, which is a dimer (two joined subunits) of the short chain from the binding domain of deoxymab 3E10, and PAT-DX3, which is a full-sized Immunoglobulin G antibody. Deoxymabs, such as PAT-DX1 and PAT-DX3, can be used to target nanoparticles carrying a payload of anti-cancer drugs specifically to tumors. Its PAT-DX1- nanoparticles (NP) pipeline involves using its PAT-DX1 to develop a new drug based on the targeted delivery of NP carrying therapeutic payloads to the inside of cancer cells.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile

See benefits

Announcements

Filter Results

All Price Sensitive Only

PAB	$4.29 Million Fully Underwritten Rights Issue	PRICE SENSITIVE	22/06/20	138.68KB	Share
PAB	Investor Presentation - June 2020	PRICE SENSITIVE	18/06/20	5.14MB	Share
PAB	Trading Halt	PRICE SENSITIVE	18/06/20	275.21KB	Share
PAB	Appendix 3G		10/06/20	126.89KB	Share
PAB	Change of Auditor		28/05/20	109.07KB	Share
PAB	US grants fund PAT-DX1 and PAT-DX1-NP targeting brain tumors		18/05/20	157.53KB	Share
PAB	New appointment to Scientific Advisory Board		11/05/20	118.98KB	Share
PAB	Appendix 4C - Quarterly - 31 March 2020	PRICE SENSITIVE	27/04/20	223.23KB	Share
PAB	Ceasing to be a substantial holder		16/03/20	531.84KB	Share
PAB	PAT-DX1 mechanism for crossing blood brain barrier confirmed	PRICE SENSITIVE	16/03/20	258.28KB	Share
PAB	PAT-DX1-NP crosses BBB and targets tumours	PRICE SENSITIVE	02/03/20	229.63KB	Share
PAB	Appendix 4D - Half Year Accounts - 31 December 2019	PRICE SENSITIVE	24/02/20	585.47KB	Share
PAB	Appendix 4C - Quarterly - 31 December 2019	PRICE SENSITIVE	30/01/20	269.8KB	Share
PAB	PAT-DX1 to be Showcased at International Conference		20/01/20	246.84KB	Share
PAB	Results of Annual General Meeting		21/11/19	214.07KB	Share
PAB	Chairman's Address and CEO Presentation to 2019 AGM		21/11/19	1.28MB	Share
PAB	Patrys Receives R&D Tax Incentive Refund	PRICE SENSITIVE	07/11/19	146.68KB	Share
PAB	Appendix 4C - Quarterly - 30 September 2019	PRICE SENSITIVE	29/10/19	278.62KB	Share
PAB	Notice of Annual General Meeting/Proxy Form		18/10/19	369.51KB	Share
PAB	Change of Director's Interest Notice		14/10/19	185.9KB	Share
PAB	Appendix 3B		09/10/19	228.67KB	Share
PAB	Initial Director's Interest Notice		04/10/19	176.51KB	Share
PAB	Dr. Pamela M. Klein appointed as Non-Executive Director		01/10/19	158.53KB	Share
PAB	Appendix 3B		17/09/19	226.8KB	Share
PAB	PAB Business Review - 30 June 2019		23/08/19	8.86MB	Share
PAB	Appendix 4G and Corporate Governance Statement		23/08/19	513.56KB	Share
PAB	Appendix 4E and 2019 Annual Report	PRICE SENSITIVE	23/08/19	1.1MB	Share
PAB	Patrys presented at leading brain metastases conference		19/08/19	711.32KB	Share
PAB	Appendix 4C - Quarterly - 30 June 2019	PRICE SENSITIVE	30/07/19	173.33KB	Share
PAB	Updated investor presentation and attendance at Bioshares		24/07/19	1.54MB	Share
PAB	PAT-DX1 significantly improves survival in aggressive GBM	PRICE SENSITIVE	22/07/19	288.63KB	Share
PAB	Europe grants patent for Deoxymab 3E10	PRICE SENSITIVE	17/07/19	615.05KB	Share
PAB	Becoming a substantial holder		12/07/19	211.28KB	Share
PAB	Ceasing to be a substantial holder from MQG		10/07/19	1.09MB	Share
PAB	Ceasing to be a substantial holder		09/07/19	325.84KB	Share
PAB	Updated Securities Trading Policy		01/07/19	149.79KB	Share
PAB	Investor Update		26/06/19	801.32KB	Share
PAB	PAT-DX1 Reduces Brain Metastases, Enhances Radiation Therapy	PRICE SENSITIVE	30/05/19	254.91KB	Share
PAB	Appendix 4C - Quarterly - 31 March 2019	PRICE SENSITIVE	24/04/19	235.56KB	Share
PAB	Presentation at AACR conference		01/04/19	139.41KB	Share
PAB	Market Update	PRICE SENSITIVE	29/03/19	243.59KB	Share
PAB	Patrys Video Explaining 3E10 Platform		20/03/19	234.15KB	Share
PAB	Appendix 3B		15/03/19	209.29KB	Share
PAB	Appendix 4D - Half Year Accounts - 31 December 2018	PRICE SENSITIVE	20/02/19	487.29KB	Share
PAB	Section 708A Cleansing Statement and Appendix 3B		30/01/19	402.29KB	Share
PAB	Appendix 4C - Quarterly - 31 December 2018	PRICE SENSITIVE	30/01/19	279.89KB	Share
PAB	Corporate Overview - January 2019		09/01/19	1.3MB	Share
PAB	Patrys Presenting at Biotech Showcase		08/01/19	105.89KB	Share
PAB	Patrys Receives R&D Tax Incentive Refund	PRICE SENSITIVE	08/01/19	108.29KB	Share
PAB	PAT-DX1 Suppresses Breast Cancer Brain Metastases	PRICE SENSITIVE	20/12/18	248.11KB	Share
PAB	Change of Director's Interest Notices x4		14/12/18	76.07KB	Share
PAB	Appendix 3B		11/12/18	217.16KB	Share
PAB	Results of Annual General Meeting		22/11/18	208.85KB	Share
PAB	Chairman's Address and CEO Presentation to 2018 AGM		22/11/18	1.99MB	Share
PAB	Appendix 4C - Quarterly - 30 September 2018	PRICE SENSITIVE	31/10/18	233.2KB	Share
PAB	Settlement of Manufacturing Claims	PRICE SENSITIVE	25/10/18	102.79KB	Share
PAB	Notice of Annual General Meeting/Proxy Form		23/10/18	590.56KB	Share
PAB	Patrys Awarded Federal Grant		08/10/18	146.24KB	Share
PAB	PAT-DX1 Clinical Target Indications Confirmed	PRICE SENSITIVE	04/10/18	252.8KB	Share
PAB	PAB Business Review - 30 June 2018		13/09/18	1.09MB	Share
PAB	Change in substantial holding from MQG		03/09/18	527.43KB	Share
PAB	Section 708A Cleansing Statement and Appendix 3B		03/09/18	285.4KB	Share
PAB	Change in substantial holding		31/08/18	513.73KB	Share
PAB	Patrys and WEHI Awarded Grant	PRICE SENSITIVE	28/08/18	252.24KB	Share
PAB	Appendix 4G and Corporate Governance Statement		24/08/18	483.29KB	Share
PAB	Appendix 4E and 2018 Annual Report	PRICE SENSITIVE	24/08/18	1.1MB	Share
PAB	Patent Granted for Pre-clinical IgM Candidate PAT-LM1	PRICE SENSITIVE	01/08/18	710.34KB	Share
PAB	Appendix 4C - Quarterly - 30 June 2018	PRICE SENSITIVE	26/07/18	235.01KB	Share
PAB	Preliminary PAT-DX1 pharmacokinetics	PRICE SENSITIVE	05/07/18	165.25KB	Share
PAB	China and Japan both grant patents for Deoxymab 3E10	PRICE SENSITIVE	03/07/18	140.91KB	Share
PAB	Change of Director's Interest Notice		28/06/18	29.32KB	Share
PAB	Cancellation of Employee Share Scheme Shares		27/06/18	114.44KB	Share
PAB	Final share buy-back notice - Appendix 3F		27/06/18	94.91KB	Share
PAB	Daily share buy-back notice - Appendix 3E		27/06/18	96.25KB	Share
PAB	Corporate Overview - June 2018		12/06/18	4.77MB	Share
PAB	Employee share scheme buy-back - Appendix 3C		08/06/18	226.74KB	Share
PAB	Appendix 3B		01/06/18	506.01KB	Share
PAB	PAT-DX1 Targets and Kills Brain Cancer Stem Cells	PRICE SENSITIVE	31/05/18	142.76KB	Share
PAB	Becoming a substantial holder from MQG		28/05/18	542.5KB	Share
PAB	Change in substantial holding		28/05/18	99.33KB	Share
PAB	Change in substantial holding		25/05/18	848.96KB	Share
PAB	Becoming a substantial holder		23/05/18	222.58KB	Share
PAB	Section 708A Cleansing Statement and Appendix 3B		23/05/18	916.66KB	Share
PAB	Completion of Placement		23/05/18	98.35KB	Share
PAB	Patrys Increases Capital Raising to $4.6 million	PRICE SENSITIVE	21/05/18	100.89KB	Share
PAB	New Pre-Clinical Collaboration on PAT-DX1	PRICE SENSITIVE	17/05/18	138.9KB	Share
PAB	Patrys Completes $3.5M Placement	PRICE SENSITIVE	16/05/18	99.71KB	Share
PAB	Trading Halt	PRICE SENSITIVE	14/05/18	266.61KB	Share
PAB	Investor Update		10/05/18	3.38MB	Share
PAB	Appendix 4C - Quarterly - 31 March 2018	PRICE SENSITIVE	27/04/18	306.6KB	Share
PAB	Patrys Presents at AACR Conference		17/04/18	665KB	Share
PAB	Patrys Receives R&D Tax Incentive Refund	PRICE SENSITIVE	05/04/18	100.95KB	Share
PAB	PAT-DX1 Improves Survival in Animal Model of Glioblastoma	PRICE SENSITIVE	19/03/18	246.2KB	Share
PAB	Appendix 3B		16/03/18	506.95KB	Share
PAB	PAT-DX1 Crosses Blood Brain Barrier to Reduce Tumour Size	PRICE SENSITIVE	28/02/18	139.11KB	Share
PAB	Change in substantial holding		27/02/18	98.47KB	Share
PAB	Change to Exercise Price of Unlisted Options		27/02/18	99.15KB	Share
PAB	Appendix 4D - Half Year Accounts - 31 December 2017	PRICE SENSITIVE	23/02/18	707.08KB	Share
PAB	Change of Director's Interest Notices x3		20/02/18	350.87KB	Share
PAB	Change in substantial holding		20/02/18	864.06KB	Share

PAB $4.29 Million Fully Underwritten Rights Issue
22/06/20	PRICE SENSITIVE	138.68KB	Share
PAB Investor Presentation - June 2020
18/06/20	PRICE SENSITIVE	5.14MB	Share
PAB Trading Halt
18/06/20	PRICE SENSITIVE	275.21KB	Share
PAB Appendix 3G
10/06/20		126.89KB	Share
PAB Change of Auditor
28/05/20		109.07KB	Share
PAB US grants fund PAT-DX1 and PAT-DX1-NP targeting brain tumors
18/05/20		157.53KB	Share
PAB New appointment to Scientific Advisory Board
11/05/20		118.98KB	Share
PAB Appendix 4C - Quarterly - 31 March 2020
27/04/20	PRICE SENSITIVE	223.23KB	Share
PAB Ceasing to be a substantial holder
16/03/20		531.84KB	Share
PAB PAT-DX1 mechanism for crossing blood brain barrier confirmed
16/03/20	PRICE SENSITIVE	258.28KB	Share
PAB PAT-DX1-NP crosses BBB and targets tumours
02/03/20	PRICE SENSITIVE	229.63KB	Share
PAB Appendix 4D - Half Year Accounts - 31 December 2019
24/02/20	PRICE SENSITIVE	585.47KB	Share
PAB Appendix 4C - Quarterly - 31 December 2019
30/01/20	PRICE SENSITIVE	269.8KB	Share
PAB PAT-DX1 to be Showcased at International Conference
20/01/20		246.84KB	Share
PAB Results of Annual General Meeting
21/11/19		214.07KB	Share
PAB Chairman's Address and CEO Presentation to 2019 AGM
21/11/19		1.28MB	Share
PAB Patrys Receives R&D Tax Incentive Refund
07/11/19	PRICE SENSITIVE	146.68KB	Share
PAB Appendix 4C - Quarterly - 30 September 2019
29/10/19	PRICE SENSITIVE	278.62KB	Share
PAB Notice of Annual General Meeting/Proxy Form
18/10/19		369.51KB	Share
PAB Change of Director's Interest Notice
14/10/19		185.9KB	Share
PAB Appendix 3B
09/10/19		228.67KB	Share
PAB Initial Director's Interest Notice
04/10/19		176.51KB	Share
PAB Dr. Pamela M. Klein appointed as Non-Executive Director
01/10/19		158.53KB	Share
PAB Appendix 3B
17/09/19		226.8KB	Share
PAB PAB Business Review - 30 June 2019
23/08/19		8.86MB	Share
PAB Appendix 4G and Corporate Governance Statement
23/08/19		513.56KB	Share
PAB Appendix 4E and 2019 Annual Report
23/08/19	PRICE SENSITIVE	1.1MB	Share
PAB Patrys presented at leading brain metastases conference
19/08/19		711.32KB	Share
PAB Appendix 4C - Quarterly - 30 June 2019
30/07/19	PRICE SENSITIVE	173.33KB	Share
PAB Updated investor presentation and attendance at Bioshares
24/07/19		1.54MB	Share
PAB PAT-DX1 significantly improves survival in aggressive GBM
22/07/19	PRICE SENSITIVE	288.63KB	Share
PAB Europe grants patent for Deoxymab 3E10
17/07/19	PRICE SENSITIVE	615.05KB	Share
PAB Becoming a substantial holder
12/07/19		211.28KB	Share
PAB Ceasing to be a substantial holder from MQG
10/07/19		1.09MB	Share
PAB Ceasing to be a substantial holder
09/07/19		325.84KB	Share
PAB Updated Securities Trading Policy
01/07/19		149.79KB	Share
PAB Investor Update
26/06/19		801.32KB	Share
PAB PAT-DX1 Reduces Brain Metastases, Enhances Radiation Therapy
30/05/19	PRICE SENSITIVE	254.91KB	Share
PAB Appendix 4C - Quarterly - 31 March 2019
24/04/19	PRICE SENSITIVE	235.56KB	Share
PAB Presentation at AACR conference
01/04/19		139.41KB	Share
PAB Market Update
29/03/19	PRICE SENSITIVE	243.59KB	Share
PAB Patrys Video Explaining 3E10 Platform
20/03/19		234.15KB	Share
PAB Appendix 3B
15/03/19		209.29KB	Share
PAB Appendix 4D - Half Year Accounts - 31 December 2018
20/02/19	PRICE SENSITIVE	487.29KB	Share
PAB Section 708A Cleansing Statement and Appendix 3B
30/01/19		402.29KB	Share
PAB Appendix 4C - Quarterly - 31 December 2018
30/01/19	PRICE SENSITIVE	279.89KB	Share
PAB Corporate Overview - January 2019
09/01/19		1.3MB	Share
PAB Patrys Presenting at Biotech Showcase
08/01/19		105.89KB	Share
PAB Patrys Receives R&D Tax Incentive Refund
08/01/19	PRICE SENSITIVE	108.29KB	Share
PAB PAT-DX1 Suppresses Breast Cancer Brain Metastases
20/12/18	PRICE SENSITIVE	248.11KB	Share
PAB Change of Director's Interest Notices x4
14/12/18		76.07KB	Share
PAB Appendix 3B
11/12/18		217.16KB	Share
PAB Results of Annual General Meeting
22/11/18		208.85KB	Share
PAB Chairman's Address and CEO Presentation to 2018 AGM
22/11/18		1.99MB	Share
PAB Appendix 4C - Quarterly - 30 September 2018
31/10/18	PRICE SENSITIVE	233.2KB	Share
PAB Settlement of Manufacturing Claims
25/10/18	PRICE SENSITIVE	102.79KB	Share
PAB Notice of Annual General Meeting/Proxy Form
23/10/18		590.56KB	Share
PAB Patrys Awarded Federal Grant
08/10/18		146.24KB	Share
PAB PAT-DX1 Clinical Target Indications Confirmed
04/10/18	PRICE SENSITIVE	252.8KB	Share
PAB PAB Business Review - 30 June 2018
13/09/18		1.09MB	Share
PAB Change in substantial holding from MQG
03/09/18		527.43KB	Share
PAB Section 708A Cleansing Statement and Appendix 3B
03/09/18		285.4KB	Share
PAB Change in substantial holding
31/08/18		513.73KB	Share
PAB Patrys and WEHI Awarded Grant
28/08/18	PRICE SENSITIVE	252.24KB	Share
PAB Appendix 4G and Corporate Governance Statement
24/08/18		483.29KB	Share
PAB Appendix 4E and 2018 Annual Report
24/08/18	PRICE SENSITIVE	1.1MB	Share
PAB Patent Granted for Pre-clinical IgM Candidate PAT-LM1
01/08/18	PRICE SENSITIVE	710.34KB	Share
PAB Appendix 4C - Quarterly - 30 June 2018
26/07/18	PRICE SENSITIVE	235.01KB	Share
PAB Preliminary PAT-DX1 pharmacokinetics
05/07/18	PRICE SENSITIVE	165.25KB	Share
PAB China and Japan both grant patents for Deoxymab 3E10
03/07/18	PRICE SENSITIVE	140.91KB	Share
PAB Change of Director's Interest Notice
28/06/18		29.32KB	Share
PAB Cancellation of Employee Share Scheme Shares
27/06/18		114.44KB	Share
PAB Final share buy-back notice - Appendix 3F
27/06/18		94.91KB	Share
PAB Daily share buy-back notice - Appendix 3E
27/06/18		96.25KB	Share
PAB Corporate Overview - June 2018
12/06/18		4.77MB	Share
PAB Employee share scheme buy-back - Appendix 3C
08/06/18		226.74KB	Share
PAB Appendix 3B
01/06/18		506.01KB	Share
PAB PAT-DX1 Targets and Kills Brain Cancer Stem Cells
31/05/18	PRICE SENSITIVE	142.76KB	Share
PAB Becoming a substantial holder from MQG
28/05/18		542.5KB	Share
PAB Change in substantial holding
28/05/18		99.33KB	Share
PAB Change in substantial holding
25/05/18		848.96KB	Share
PAB Becoming a substantial holder
23/05/18		222.58KB	Share
PAB Section 708A Cleansing Statement and Appendix 3B
23/05/18		916.66KB	Share
PAB Completion of Placement
23/05/18		98.35KB	Share
PAB Patrys Increases Capital Raising to $4.6 million
21/05/18	PRICE SENSITIVE	100.89KB	Share
PAB New Pre-Clinical Collaboration on PAT-DX1
17/05/18	PRICE SENSITIVE	138.9KB	Share
PAB Patrys Completes $3.5M Placement
16/05/18	PRICE SENSITIVE	99.71KB	Share
PAB Trading Halt
14/05/18	PRICE SENSITIVE	266.61KB	Share
PAB Investor Update
10/05/18		3.38MB	Share
PAB Appendix 4C - Quarterly - 31 March 2018
27/04/18	PRICE SENSITIVE	306.6KB	Share
PAB Patrys Presents at AACR Conference
17/04/18		665KB	Share
PAB Patrys Receives R&D Tax Incentive Refund
05/04/18	PRICE SENSITIVE	100.95KB	Share
PAB PAT-DX1 Improves Survival in Animal Model of Glioblastoma
19/03/18	PRICE SENSITIVE	246.2KB	Share
PAB Appendix 3B
16/03/18		506.95KB	Share
PAB PAT-DX1 Crosses Blood Brain Barrier to Reduce Tumour Size
28/02/18	PRICE SENSITIVE	139.11KB	Share
PAB Change in substantial holding
27/02/18		98.47KB	Share
PAB Change to Exercise Price of Unlisted Options
27/02/18		99.15KB	Share
PAB Appendix 4D - Half Year Accounts - 31 December 2017
23/02/18	PRICE SENSITIVE	707.08KB	Share
PAB Change of Director's Interest Notices x3
20/02/18		350.87KB	Share
PAB Change in substantial holding
20/02/18		864.06KB	Share

REFRESH

First 2 3 4 5 6

(20min delay)
Last 0.9¢		Change 0.000(0.00%)		Mkt cap ! $18.51M

Open	High	Low	Value	Volume
0.9¢	0.9¢	0.9¢	$18.68K	2.075M

Buyers (Bids)

No.	Vol.	Price($)
11	2642383	0.8¢

Sellers (Offers)

Price($)	Vol.	No.
0.9¢	856022	2

View Market Depth

No.	Vol.	Price($)
11	2642383	0.008
17	4746715	0.007
11	2787680	0.006
8	3144992	0.005
5	4324000	0.004

Price($)	Vol.	No.
0.009	856022	2
0.010	1830082	5
0.011	1380000	4
0.012	372407	3
0.013	990000	2

Last trade - 16.10pm 26/04/2024 (20 minute delay)


Last 0.9¢		Change 0.000 ( 0.00 %)
Open	High	Low	Volume
0.9¢	0.9¢	0.9¢	97616
Last updated 11.58am 26/04/2024 ?

PAB (ASX) Chart

PATRYS LIMITED - Announcements

Corporate SpotlightNot Yet Available

Announcements

Buyers (Bids)

Sellers (Offers)

Top Stories

Corporate Spotlight
Not Yet Available